Compare VRTX & ADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | ADI |
|---|---|---|
| Founded | 1989 | 1965 |
| Country | United States | United States |
| Employees | 6100 | N/A |
| Industry | EDP Services | Semiconductors |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 115.2B |
| IPO Year | 1991 | 1972 |
| Metric | VRTX | ADI |
|---|---|---|
| Price | $457.11 | $276.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 21 |
| Target Price | ★ $494.64 | $282.00 |
| AVG Volume (30 Days) | 1.6M | ★ 4.7M |
| Earning Date | 02-09-2026 | 11-25-2025 |
| Dividend Yield | N/A | ★ 1.44% |
| EPS Growth | N/A | ★ 39.02 |
| EPS | ★ 14.22 | 4.56 |
| Revenue | ★ $11,723,300,000.00 | $11,019,707,000.00 |
| Revenue This Year | $11.01 | $17.89 |
| Revenue Next Year | $8.74 | $8.87 |
| P/E Ratio | ★ $32.08 | $60.18 |
| Revenue Growth | 10.33 | ★ 16.89 |
| 52 Week Low | $362.50 | $158.65 |
| 52 Week High | $519.68 | $284.23 |
| Indicator | VRTX | ADI |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 60.98 |
| Support Level | $445.41 | $270.14 |
| Resistance Level | $459.05 | $284.23 |
| Average True Range (ATR) | 10.50 | 5.34 |
| MACD | 0.26 | -1.26 |
| Stochastic Oscillator | 83.14 | 39.33 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.